Rahimi Borumand Mehrasa, Motaghinejad Majid, Motevalian Manijeh, Gholami Mina
Department of Pharmaceutical Biomaterials and Medical Biomaterial Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Iran J Med Sci. 2019 Mar;44(2):146-154.
The neuroprotective effects of duloxetine, as an antidepressant agent, and the neurodegenerative effects of methamphetamine have been shown in previous studies. Nonetheless, their exact neurochemical and behavioral effects are still unclear. In the current study, we sought to clarify the molecular mechanisms involved in the protective effects of duloxetine against methamphetamine-induced neurodegeneration.
Forty adult male rats were divided randomly into 5 groups. Group 1 was the negative control and received normal saline, Group 2 was the positive control and received methamphetamine, and Groups 3, 4, and 5 were concurrently treated with methamphetamine (10 mg/kg) and duloxetine (5, 10, and 15 mg/kg, respectively). All the treatments were continued for 21 days. Between days 17 and 21, the Morris Water Maze (MWM) was used to assess learning and memory in the treated groups. On day 22, the hippocampus was isolated from each rat and oxidative, antioxidant, and inflammatory factors were measured. Additionally, the expression levels of the total and phosphorylated forms of the Akt and GSK3 proteins were evaluated via the ELISA method.
Duloxetine in all the administered doses ameliorated the effects of the methamphetamine-induced cognition impairment in the MWM. The chronic abuse of methamphetamine increased malondialdehyde, tumor necrosis factor-α, and interleukin-1β, while it decreased superoxide dismutase, glutathione peroxidase, and glutathione reductase activities. Duloxetine not only prevented these malicious effects of methamphetamine but also activated the expression of Akt (both forms) and inhibited the expression of GSK3 (both forms) in the methamphetamine-treated rats.
We conclude that the Akt/GSK3 signaling pathways might have a critical role in the protective effects of duloxetine against methamphetamine-induced neurodegeneration and cognition impairment.
先前的研究已表明度洛西汀作为一种抗抑郁药具有神经保护作用,而甲基苯丙胺具有神经退行性作用。尽管如此,它们确切的神经化学和行为效应仍不清楚。在本研究中,我们试图阐明度洛西汀对甲基苯丙胺诱导的神经退行性变的保护作用所涉及的分子机制。
将40只成年雄性大鼠随机分为5组。第1组为阴性对照组,给予生理盐水;第2组为阳性对照组,给予甲基苯丙胺;第3、4和5组同时给予甲基苯丙胺(10mg/kg)和度洛西汀(分别为5、10和15mg/kg)。所有处理持续21天。在第17天至21天期间,使用莫里斯水迷宫(MWM)评估处理组的学习和记忆能力。在第22天,从每只大鼠分离出海马体,测量氧化、抗氧化和炎症因子。此外,通过ELISA方法评估Akt和GSK3蛋白的总形式和磷酸化形式的表达水平。
所有给药剂量的度洛西汀均改善了甲基苯丙胺诱导的MWM认知障碍的影响。长期滥用甲基苯丙胺会增加丙二醛、肿瘤坏死因子-α和白细胞介素-1β,同时降低超氧化物歧化酶、谷胱甘肽过氧化物酶和谷胱甘肽还原酶的活性。度洛西汀不仅预防了甲基苯丙胺的这些有害影响,还激活了甲基苯丙胺处理大鼠中Akt(两种形式)的表达并抑制了GSK3(两种形式) 的表达。
我们得出结论,Akt/GSK3信号通路可能在度洛西汀对甲基苯丙胺诱导的神经退行性变和认知障碍的保护作用中起关键作用。